Amanda Leiter is an Endocrinology/Metabolic physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Ucla Medical Plz Ste 530
Los Angeles, CA 900958344
Telephone
310-825-7922Provider last certified this registry record 3 Sept 2025.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
73.3%Insulin Analog25.6%Novolog Flexpen31%Lantus Solostar23%Basaglar Kwikpen U-10016%Tresiba Flextouch U-2007%Humalog Kwikpen U-1007%Insulin Lispro Kwikpen U-1007%Novolog6%Tresiba Flextouch U-1006%Part D<11 patientsGLP-1 receptor agonist19.5%Ozempic64%Trulicity26%Mounjaro11%Part D<11 patients+ 5 more classes in this area
Cardiovascular
19.9%Statin10.5%Atorvastatin Calcium56%Rosuvastatin Calcium44%Part D<11 patientsACE inhibitor3.8%Lisinopril100%Part D<11 patients+ 2 more classes in this area
Hormonal (systemic)
5.4%l-Thyroxine3.8%Levothyroxine Sodium100%Part D≥11 patientsAntihypoglycemic Agent1.5%Glucagon Emergency Kit100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Optimizing diabetes treatment strategies in complex comorbidity
University of California Los Angeles
FY2026$166,002K08DK137022 - Optimizing diabetes treatment strategies in complex comorbidity
University of California Los Angeles
FY2025$42,404K08DK137022
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”